Status:
UNKNOWN
Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease
Lead Sponsor:
Rabin Medical Center
Conditions:
Graft Vs Host Disease
Eligibility:
All Genders
17-80 years
Phase:
PHASE2
Brief Summary
The prognosis of severe (grade 3-4) and steroid refractory acute graft-versus-host disease (GVHD) continues to be dismal. Sitagliptin given as GVHD-prophylaxis has recently been shown to reduce the in...
Detailed Description
The prognosis of severe (grade 3-4) and steroid refractory acute GVHD continues to be dismal. Sitagliptin given as GVHD-prophylaxis has recently been shown to reduce the incidence of acute GVHD to les...
Eligibility Criteria
Inclusion
- Age ≥ 18-year old
- Grade 3-4 acute GVHD
- Refractory grade 2-4 acute GVHD
- Signed informed consent.
- Complete remission of the disease for which the patient was transplanted for.
Exclusion
- Patients with diabetes mellitus requiring therapy with oral hypoglycemic medications or Insulin on top of sitagliptin.
- Serious hypersensitivity reaction to sitagliptin such as angioedema or anaphylaxis.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04448587
Start Date
October 1 2020
End Date
December 31 2021
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petah Tikva, Israel